| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Features national market profiles, market sizes and market forecasts to 2009
Successful new antiparasitics have driven growth in the animal health industry
over the last decade, but many of the best sellers are now coming off-patent.
How will this key market develop over the next few years - will its value be
eroded by price competition amongst generic producers, or will new products,
new formulations and new delivery technologies continue to boost the market?
This Animal Pharm report answers all your questions on this $4.7 billion
market. It features:
- Detailed analyses of the leading 10 national markets, including market
forecasts to 2009
- Profiles of the leading companies in the sector
- Profiles of the leading antiparasitics on the market
- A review of the most commercially important parasites
Key findings
- Double digit growth in 2004 saw pet flea/tick product sales reach $1,025
million in the US, boosted by the combination products Frontline Plus (with
sales close to $300 million) and Advantage/ Advantix (with sales approaching
$200 million)
- The world's best-selling antiparasitics are Merial's Frontline, with sales
of $679 million in 2004, and Bayer's Advantage, with sales of $225 million
- The Brazilian antiparasitics market is forecast to grow at the highest
rate over the next five years, with a CAGR of 8% taking the market to $301
million by 2009
- France is the second largest national market, with 2004 sales of €224
million ($278 million), €75 million ($93 million) of which were flea/tick
treatments
- In Australia in 2004, sales of large animal endoparasiticides were Aus$92
million (US$68 million), whilst endectocides reached Aus$57 million (US$42
million)
|
